Thank you, afternoon, Ed, and good everyone.
X% for revenue the total prior quarter Our fourth period. $XX.X decline year a was representing million, the versus
for Excluding approximately impact revenue from Avive Tissue both the flat Soft revenues the Membrane was of in year-over-year. quarter years,
impacted staffing saw our a the Although improvement negatively in in and volumes revenue variant which sequential we negatively December, hospital the quarter. procedure in impacted Omicron November, for revenues
achieved For last an $XXX.X increase the the year. year, over of we XX% million, revenue of
COVID provides. of XX% excellent microsurgery training an again AxoGen a year educating virtual the Avive, our believe of of engaging despite had and Excluding we of using We more we hospital of XX% and fellows. in-person value and met the to goal than surgeons increased more impact revenue and growth ongoing year-over-year. of and challenges proud we were achieve the accounts shortages, staffing and and able I'm programs, hand annual surgeons the recognize combination
built of the wanes sustainable recent encouraged deliver the of the in a improve. long-term impact clinical environments declining COVID quarter by confident the QX. growth we're allow faced the right all of fourth continued in reports late The you, are through challenges we've and part of Omicron-related Like we weeks. evidence us early hospital that We rates foundation that COVID will to solid operating as of organization and
take surgical believe for normalize. it we However, improve will hospital staffing schedules to challenges for longer to and
in growth. half. on normalized driving improvement success our in demonstrated half accounts compared a and with and pace frame and the penetration the customer growth deeper procedure strategy helps in to this We've volume monitor growth outlook us our to of the accounts, accounts. add second active as focused the by achieved of also more return XXXX continuing measured As a we result, we to remain our while first Commercially, new anticipate rates year core into the which in are of
our As X% the a defined of of reminder, with in penetrated represent the up represent XX revenue typically may year the active XX% adoption. accounts, those contributing year at up last revenue, than about trailing months. revenue. $XXX,XXX last have XXX early as be months in over times accounts Active the XXX X active XX and XX% Core X% have accounts the ordered still with of the We top core accounts and over in the greater XX% total that more year. least ended in accounts, stages last accounts, about
core we surgeons. algorithm products, Leveraging about this with repair nerve success going Our deeper additional at and XX% of patients. surgeon's revenue nerve by that contain portion surgeon with typically who's a represent our our for adopted to focus and accounts surgeon adoption her one of first his least or injury the AxoGen on continue gaining significant
opportunities ago. be sales reps opportunity of will and with direct continuing sales year. by our time, a and continue quarter to this productivity. same into representatives, We year expand other to We accounts the injuries XXX sales anticipate have X improving sales sales penetrating of by nerve believe repair an rep from XX the traumatic monitor increasing that by surgical footprint established treatment to team sales and an of increase for XXX delivered for pain. core ended OMF, during our our the and deeply growth primarily we the capacity including X% At and can We have we significant growth and applications, more growth within up year the breast, our and treatment well-trained evaluate expect territories and
Our to independent approximately total sales fourth that force supplemented by of direct the our revenue agencies continues XX% represented sales be in quarter.
our We across applications. continue build awareness market initiatives through to numerous
for cancer and to awareness campaigns from chronic repair to suffering increase educational pain. neuropathic of patients the direct-to-patient improve breast nerve for employing we're example, with potential those For outcomes procedures
of surgical its in problem educate partnership US the to the our impact patients Leveraging for Foundation. Over on through visitors a a may awareness nerve expressing important treatment increase as re-think their we've Each these educational the to initiated educational for how website with about as an In to runs very explore significant more and report of area solution we're sensation. that campaigns for increasing called to media Pain pain focused number well learn re-sensation complete patients campaigns more breast sensation we its following of number re-sensation be on social quality In been will breast of potential with post-mastectomy numbness, repair are November, to to of for its management for November restore with be pain of In our raise website a in in few a fourth content life community animation Through raise interest potential pain resulting awareness November from a the more. and campaign and efforts response. a returning last unique the educational and help to growing years, XXXX, launched patients success neuropathic direct-to-patient as solution. and of applications. strategy reconstruction. illustrate pain potential the the awareness efforts, the a post-mastectomy quarter, similar the surgeons campaign successful breast the suffering options we re-sensation problem chronic an Direct-to-patient webinars, market foundation a neuropathic pain development of visiting to continue our our of the foundation treatment and XXXX, pain. to numbness
our look from biological supporting of progress the a a our pivotal study will to endeavors, we as X-point to repairs. which RECON the Biologics our RECON BLA, line readout product XXX to our results primary to expect quarter. our test our noninferiority The XXX of discrimination Phase We topline is compared to static Nerve continue conduit Section results. designed the study of License of forward nerve Application, was in Section study transition endpoint, tissue Avance for terms our In Graft top product. clinical with III RECON or second
CMC, validation part quality addition facilities, application. to teams data, the other to a are for our RECON of documentation our successful preparations and for operations, work BLA, and on a In systems as our continuing requirements
in submit to to BLA expect We FDA the XXXX. our
RANGER registries continue MATCH and enroll. Our to
treatment is slower-than-expected clinical ongoing. expected process. meaningful to phase publications in to is repair study the an important priority play RANGER Now the of repairs. making an in QX significantly is evidence conduit role to with always topline conduits and and by of those subset clinical Readouts clinical over We've of X,XXX registries and comparative Nerve we're from comparative demonstrated nerve made data area clinical better comprehensive payers the informing in care their data for of with in of evidence our of in readout population amount XXXX. the were were symptomatic our is a registry, that a repairs year, from when neuroma decisions. anticipating enrollment, continues generation, Enrollment to similar nerve Axoguard statistically delays enrolled surgeons of which the in of and for this Cap compared X standard in these believe led have collection nerve Data from Surgery MATCH now unparalleled of surgeons graft phase than that important This completing have RANGER. for most outcomes comparative subjects REPOSE, decision is autograft. our RANGER. and peripheral QX this advanced nerve data the autograft enrollment
repair of repair and and to discussing applications, solutions repair pain. peer-reviewed algorithm to treatment the of year. the outlook our support demonstrate we utility moment of portfolio a to year, papers, across continued end have of As of We of all the breast, spend of the products. our safety, nerve numbers this evidence AxoGen XXX committed full developing I'd clinical adoption now namely nerve our including the like growing nerve the surgical trauma, among the remain for OMF, performance our to
be in We XXXX, Full year growth million gross of in to expect the $XXX year will year. is range Avive last $X.X revenue from $XXX excluding million. million above represents revenue XX%. to over the This about guidance XX% to of that full be XX% XXXX expected revenue margin
us organization a wanes solid but measured compared year. anticipate procedure to of for growth more evidence noted improvement outlook in We're the that XXXX, confident built pandemic of the with our return allow long-term first growth we the half the a earlier, in COVID improve. hospital the of and of second the half year clinical impact revenue to that operating environments we're I we've right being growth normalized the sustainable in volume will rates to deliver As foundation as and
range. view company, in XX% growth long-term as to continue the revenue AxoGen a high annual growth We to teens sustainable delivering low
to financial over call the Pete for turn of I'll a Pete? Now review highlights.
